InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-38.2%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Dunne Michael W., Director. Officer active across 1 company, notably Iterum Therapeutics plc. In total, 15 disclosures have been recorded. Split: 4 buys · 0 sell. Total volume traded: €108k. History available since 25 July 2021. The latest transaction was disclosed on 22 December 2023 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations15 total
106,247 sharesOrdinary SharesSEC:0000950170-24-095096:0
25,000 shares@ US$1.4029.4% of flowOrdinary SharesSEC:0001209191-23-059750:0
Ideal exit: 17 Sept 2024 (T+270)
10,000 shares@ US$1.844215.6% of flowOrdinary SharesSEC:0001209191-23-059133:0
Ideal exit: 13 Sept 2024 (T+270)
20,000 shares@ US$2.034534.4% of flowOrdinary SharesSEC:0001209191-23-056685:0
Ideal exit: 18 Aug 2024 (T+270)
3,487 sharesOrdinary SharesSEC:0001209191-23-050911:0
1,779 sharesOrdinary SharesSEC:0001209191-23-040406:0
15,853 shares0Ordinary SharesSEC:0001209191-23-037407:0
1,299 shares0Ordinary SharesSEC:0001209191-23-034106:0
1,299 shares0Ordinary SharesSEC:0001209191-23-022422:0
761 sharesOrdinary SharesSEC:0001209191-23-001287:0
10,000 shares@ US$2.2220.5% of flowOrdinary SharesSEC:0001209191-22-049352:0
Ideal exit: 4 Jun 2023 (T+270)
36,798 sharesOrdinary SharesSEC:0001209191-22-039312:0
10,494 shares0Ordinary SharesSEC:0001209191-22-021542:0
80,000 shares0Ordinary SharesSEC:0000899243-21-030223
80,000 shares0Ordinary SharesSEC:0000899243-21-030223:0
15 of 15 declarations
About Dunne Michael W.
Michael W. Dunne is a Board Member at Iterum Therapeutics plc. In this role, he contributes to overseeing the company's activities and shaping its development strategy. Dunne brings significant experience in the biotechnology field, allowing him to guide the company in its research and development initiatives. His commitment to innovation is essential for Iterum's success.
